Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years-Reference-Cited by-同舟云学术

Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years

Published:2020-09-03 Issue: Volume: Page:135245852095417
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Hawton Annie¹^ORCID,Goodwin Elizabeth²,Boddy Kate³,Freeman Jennifer⁴,Thomas Sarah⁵,Chataway Jeremy⁶,Green Colin⁷

Affiliation:

1. Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK/NIHR Applied Research Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK

2. Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK

3. NIHR Applied Research Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK

4. School of Health Professions, Faculty of Health, University of Plymouth, Plymouth, UK

5. Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK

6. Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK/National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK

7. Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK/Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK

Abstract

Background: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effects in cost-effectiveness analyses and in 2012, in the United Kingdom, the National Institute for Health and Care Excellence called for an improvement in the cost-effectiveness framework for assessing MS treatments. Objective and Methods: This review describes what is meant by cost-effectiveness in health/social care funding decision-making, and usual practice for assessing treatment benefits. Results: We detail the use of the quality-adjusted life-year (QALY) in resource allocation decisions, and set out limitations of this approach in the context of MS. Conclusion: We conclude by highlighting methodological and policy developments which should aid addressing these limitations.

Funder

multiple sclerosis society

national institute for health research

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458520954172

Reference34 articles.

1. Continuing the multiple sclerosis risk sharing scheme is unjustified

2. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care;Journal of Neurology, Neurosurgery & Psychiatry;2023-08-30

2. Features of multiple sclerosis in childhood in the Republic of Tatarstan;Neurology, Neuropsychiatry, Psychosomatics;2023-08-21

3. Multiple sclerosis health-related quality of life utility values from the UK MS register;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-04

4. Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies;Frontiers in Neurology;2022-10-20

5. Multicultural Quality of Life Index in Relatives of People With Borderline Personality Disorder;Frontiers in Psychiatry;2022-06-17